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Background and Objectives. To maximize graft-
versus-leukemia (GVL) effects while minimizing
the risk of graft-versus-host disease (GVHD), we
undertook a study of allogeneic CD34-selected
peripheral blood stem cell (PBSC) transplanta-
tion followed by CD8-depleted donor lymphocyte
infusion (DLI).
Design and Methods. Twenty-four patients with
advanced hematologic malignancies were
included. PBSC were collected in matched
(N=16) or one-mismatch (N=8) related donors
and CD34-selected. On day 60, donors donated
lymphocytes that were CD8-depleted and sepa-
rated into 3 aliquots containing 2×106, 1×107
and 5×107 CD3+ cells/kg (patients 1-13) or into
2 aliquots containing 1×107 and 5×107 CD3+
cells/kg (patients 14-24). The 1st aliquot was
infused on day 60 and the other 1 (2) cryopre-
served and infused on days 100 (and 140).
Results. An average of 100%, 100% and 84% of the
scheduled dose could be administered in DLI 1, 2
and 3, respectively. Although the study group was at
very high risk of GVHD, the actuarial incidence of
grade II-IV acute GVHD was 28% (13% for HLA-iden-
tical siblings) with only 1 patient developing grade
III-IV GVHD (after DLI). The actuarial 2-year proba-
bility of extensive chronic GVHD was similarly low
(13% for all patients and 0% for HLA-identical sib-
lings). Individual cases as well as a 30% relapse
rate (0% for standard-risk patients versus 55% for
high-risk patients) indicated preservation of the GVL
effect.
Interpretation and Conclusions. We conclude
that allogeneic transplantation of CD34-select-
ed PBSC followed by pre-emptive CD8-depleted
After allogeneic hematopoietic stem cell trans-plantation,1 graft-versus-host disease (GVHD)and its treatment are the major causes of
transplant-related morbidity and mortality.2 Com-
pared with bone marrow transplantation, the use of
allogeneic peripheral blood stem cells (allo-PBSC)
ensures faster hematopoietic recovery.3-8 However,
the number of T-cells injected is about 1 log high-
er, leading to an increased incidence of chronic
GVHD3-5,7,9-11 but probably also a decreased risk of
relapse.6,8 The most efficient method for prevention
of GVHD consists in T-cell depletion of the graft.12-
15 However this usually leads to greatly increased
risks of leukemia relapse and delayed immune
reconstitution.12-18 Positive selection of CD34+
hematopoietic stem cells is a novel way of per-
forming T-cell depletion that results in a 2-3 log
elimination of T and NK cells while preserving
hematologic reconstitution after transplanta-
tion.17,19-21 As with other T-cell depletion methods,
preliminary reports suggest that CD34 selection
may reduce the incidence of acute and chronic
GVHD22 but that there could be an increased risk of
relapse. 
Donor lymphocyte infusions (DLI) have been used
increasingly to treat relapses after hematopoietic
stem cell transplantation (HSCT).23-31 The main com-
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DLI is feasible with rapid engraftment and mini-
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plication of DLI is GVHD, which is often associated
with response to DLI.23,25,26,31 However, the observa-
tion in some patients of complete responses in the
absence of GVHD proves that the graft-versus-
leukemia (GVL) effect may be separated from the
development of clinical GVHD. Moreover, it is pos-
sible to reduce the risk of GVHD without impairing
the GVL effect by starting with a low dose of T-
cells and increasing the dose in a stepwise fashion
in case of no response32,33 or by CD8 depletion of
DLI.29,34,35 As DLI are effective at inducing complete
remissions in leukemic patients relapsing after allo-
geneic bone marrow transplantation, and particu-
larly so if the infusions are performed in early
relapse,23,25,26,29,31,36 it might be even more efficient
to give DLI before relapse at a time when minimal
residual disease is still present. However, it is well
demonstrated that unmanipulated DLI given early
after hematopoietic stem cell transplantation are
associated with an increased risk of GVHD23,37 and
previous studies of pre-emptive DLI resulted in a
high incidence of GVHD despite low numbers of T-
cells infused in incremental fashion.38-40
In order to take advantage of the engraftment
velocity and the GVL effect of allogeneic PBSC
while minimizing the risk of GVHD, we undertook
a study of allogeneic CD34-selected PBSC trans-




Twenty-four patients with hematologic malig-
nancies, 18 males and 6 females, aged 14 to 56
years (median 46 years) were included. Their clin-
ical characteristics are summarized in Table 1.
Twelve patients (7 with acute myeloid leukemia-
AML, 2 with acute lymphocytic leukemia-ALL, 1
with non-Hodgkin’s lymhoma-NHL in first remis-
sion and 2 with chronic myeloid leukemia-CML in
first chronic phase) were designated as standard
risk for relapse although 4 had poor prognostic
cytogenetic abnormalities. The remaining 12
patients with more advanced disease were consid-
ered as high risk, including patient #3 (ALL in first
complete remission) because of the very high num-
ber of lymphoblasts and massive cerebral leukosta-
sis at diagnosis. Transplants were carried out from
matched (#=16) or one-mismatch (#=8) related
donors (Table 1). Written informed consent was
CD8-depleted DLI after CD34-selected allo-PBSCT
Table 1. Patients and donors.
Patients Donors
No. Age/Sex Diagnosis Cytogenetic abnormality Status at transplant and other prognostic  factors Relationship Age/Sex HLA
1 14/M NHL none 2nd CR Sibling 17/M 1 mismatch 
2 18/M AML del7 1st CR Sibling 23/M HLA-id
3 15/F ALL t(1; 4), del 10 1st CR; 900,000 WBC and cerebral leukostasis at diagnosis Sibling 13/M HLA-id
4 50/F AML none 1st CR Sibling 53/M HLA-id
5 40/M AML t(8; 21); -Y 1st relapse Sibling 16/M HLA-id
6 32/M AML none 2nd relapse; 2nd allogeneic transplant Parent 70/M 1 mismatch
7 15/M ALL t(9; 22) 2nd CR Sibling 18/F HLA-id
8 53/M CML t(9; 22) 1st CP Sibling 48/F 1 mismatch
9 47/F AML none 1st CR Child 28/F 1 mismatch
10 42/M AML complex karyotype refractory disease Sibling 38/M HLA-id
11 48/M CML t(9; 22) 2nd CP Sibling 47/M HLA-id
12 27/M AML inv16 1st CR Sibling 30/M HLA-id
13 51/M CMML none refractory disease Sibling 43/F HLA-id
14 26/M ALL unsuccessful 1st CR Parent 57/F 1 mismatch
15 23/M ALL not done 2nd CR Sibling 35/M HLA-id
16 49/M CLL complex karyotype refractory disease Sibling 44/M HLA-id
17 49/F AML complex karyotype refractory disease Sibling 40/F HLA-id
18 18/M ALL complex karyotype 1stCR Sibling 14/M HLA-id
19 56/F AML none 1st CR Sibling 62/F HLA-id
20 48/F NHL none 1st CR Sibling 51/F 1 mismatch
21 44/F NHL none 2nd CR Sibling 51/F 1 mismatch
22 47/F CML t(9; 22) 1st CP Child 25/F 1 mismatch
23 51/F AML +8 1st CR Sibling 44/F HLA-id
24 50/F AML complex karyotype 1st CR Sibling 55/M HLA-id
M = male; F = female; AML = acute myeloid leukemia; CML = chronic myeloid leukemia; NHL = non-Hodgkin’s lymphoma; ALL = acute lymphoid leukemia; 
CMML = chronic myelo-monocytic leukemia; CLL = chronic lymphocytic leukemia; CR = complete remission; CP = chronic phase; del = deletion, t = translocation,
inv = inversion, HLA-id = HLA-identical.
obtained from patients and donors and our insti-
tution’s Ethical Committee approved the protocol.
Clinical management
The conditioning regimen depended on the clin-
ical diagnosis. The following regimens were used:
1) Ara-C (12 g/m2), cyclophosphamide (120 mg/m2)
and single dose total body irradiation-TBI (8 Gy)
(AML and MDS patients); 2) Ara-C (18 g/m2), mel-
phalan (140 mg/m2) and fractionated TBI (12 Gy)
(ALL patients); 3) busulfan (16 mg/kg) and
cyclophosphamide (120 mg/kg) (CML and 2nd trans-
plant patients); 4) cyclophosphamide (120 mg/kg)
and fractionated TBI (12 Gy) (NHL and CLL
patients). All patients were treated with 5 µg/kg/d
lenograstim (Granocyte®) from day +1 until the
granulocyte count was > 109/L for three consecu-
tive days or > 1010/L for one day. Six early patients
(4 not HLA-identical to their donor and 2 AML in
CR1) received a short course of methotrexate in
addition to cyclosporine (CyA). Because of the low
incidence of acute GVHD observed in the first 9
patients, GVHD prophylaxis was carried out with
CyA alone for patients 10 to 24. The diagnosis and
grading of acute and chronic GVHD was estab-
lished as previously reported.41,42 Disease evalua-
tion, including bone marrow aspirations and biop-
sies, as well as an evaluation of chimerism by flu-
orescent in situ hybridization (FISH) with X and Y
probes in patients with donors of the opposite sex,
were routinely carried out on days 40, 100, 180
and 365. Mixed chimerism (MC) was defined as
between 1% and 94% donor cells and full
chimerism (FC) as > 95% donor cells. Polymerase
chain reaction (PCR) analyses for cytomegalovirus
(CMV)  were performed weekly until day 100 and
every 2-4 weeks thereafter. Patients with a positive
PCR received prophylactic ganciclovir for a mini-
mum of 4 weeks and generally up to day 100.
Stem cell mobilization, collection and
selection
Donors received human granulocyte colony-
stimulating factor (G-CSF) (Granocyte®, kindly pro-
vided by Rhône-Poulenc-Rorer, Brussels, Belgium)
at a dose of 10-15 µg/kg from day -5 through day
-1 before transplant. Collection of PBSC was car-
ried out on days -1 and 0, using a continuous flow
blood cell separator (CS3000+, Baxter-Fenwall
Laboratories, Deerfield, IL, or Cobe Spectra, Lake-
wood, CO, USA). The volume of blood processed
was 12-16 liters. The PBSC from the first day of
harvest were stored overnight in the patient’s own
plasma. Immediately after the second harvest,
PBSC from the first and the second days of harvest
were pooled. CD34+ cell selection was carried out
using the Isolex 300i® magnetic cell separator
(Nexell International, Wemmel, Belgium), accord-
ing to the manufacturer’s recommendations. 
Donor lymphocyte infusions
Around day 60 post-transplantation, donors
underwent 12-16 liter leukophereses on 2 consec-
utive days to collect lymphocytes. The collection
from the first day of harvest was stored overnight
in the patient’s own plasma and pooled with the
second harvest before processing by CD8+ selection
using the Nexell Isolex 300i®. The CD8-negative
fraction was recovered and divided into 3 aliquots
containing 2×106, 1×107 and 5×107 CD3+ cells/kg
recipient for patients from #1 to #13. The 2nd and
3rd aliquots were cryopreserved in 10% DMSO in a
controlled-rate freezer. After an interim analysis
showed little acute or chronic GVHD associated
with DLI, the schedule of DLI was changed to 2
aliquots of 1×107 and 5×107 CD3+ cells/kg recipi-
ent for patients 14 to 21. Aliquot 1 was injected
fresh immediately after the CD8 depletion proce-
dure (around day 60). Around day 100 (and 140 for
patients 1 to 13), aliquot 2 (and 3) were thawed
and infused into the patient. CD8-depleted DLI
were not to be infused in case of an antecedent
grade III or IV acute GVHD, or an antecedent exten-
sive chronic GVHD, or active GVHD at the time of
the scheduled infusion.
Laboratory analyses
Aliquots of the pooled PBSC as well as the CD34+
selected fraction were incubated with phycoery-
thrin-conjugated anti-CD34 monoclonal antibody
(HPCA2; Becton-Dickinson, Palo-Alto, CA, USA) for
20 minutes at 20°C, washed and fixed. A total of
1×105 cells was analyzed using a FACS-scan ana-
lyzer (Becton-Dickinson). The percentage of CD34+
cells was defined with dot plot analysis using the
whole nucleated cell population. The percentage
of positive cells in the isotype control was sub-
tracted from the CD34+ percentage to give the final
percentage of CD34+ cells. Data acquisition was
performed with the Cellquest software (Becton-
Dickinson). Donor lymphocytes (before and after
CD8 depletion) were similarly examined using dou-
ble labeling with FITC- and PE- conjugated anti-
bodies after treatment with a lysing solution.
Complete blood counts were determined using a
Technicon H2 cell counter (Bayer Diagnostics,
Diegem, Belgium). Percentages of reticulocytes
were obtained by an automated cytofluorometric
method using the thiazole orange analog DEQTC.43
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Statistical analyses
Student’s t-tests were used to compare cell sub-
sets before and after CD8 depletion. The probabil-
ity of GVHD, relapse, and survival as well as the
speed of engraftment were studied by life-table
analyses and Wilcoxon rank tests were used for
comparisons between groups. Statistical analyses
were carried out with Graphpad Prism (Graphpad
Software, San Diego, CA, USA).
Results
Collection of PBSC, CD34 selection and
engraftment kinetics 
PBSC were collected by leukophereses on two
consecutive days, except in one 70-year old donor
(patient #6) who had to undergo 4 consecutive
leukophereses (and two CD34 selection procedures)
because of poor yields. Most donors experienced
bone pain and/or cephalalgia that were easily con-
trolled with paracetamol, but no other complica-
tion was noted. A median of 10.15 (5.59 to 21.02)
×106 CD34+ cells/kg and 375 (127 to 656)×106
CD3+ cells/kg were collected (Table 2). After CD34
selection, a median of 3.97 (range 1.43 to 9.40)
×106 CD34+ cells/kg and 0.20 (range 0.01 to 0.92)
×106 CD3+ cells/kg recipient were infused (Table 2).
This represents a 3.3 log reduction for CD3+ cells.
Neutrophil engraftment (> 0.5×109/L) occurred on
day 11 (range 9 to 20) (Table 2). Partial (platelets
> 20×109/L without transfusion) and complete
platelet engraftment occurred at a median of 15
(range 10 to 124) and 31 (range 14 to 500) days,
respectively. The median time to 1% reticulocytes
was 17 days (range 12 to 130) and time to last
RBC transfusions 19 days (range 6 to >365). Neu-
trophil engraftment tended to be faster in patients
receiving > 4×106 CD34+ cells/kg (11 vs 12 days, p
= 0.07) but platelet and RBC engraftments were
not affected. Neutrophil (10 vs 16 days, p<0.001)
and platelet (12 vs 29 days, p=0.009) engraftments
were faster in patients not receiving a short course
of methotrexate.
CD8-depleted DLI after CD34-selected allo-PBSCT
Table 2. Composition of PBSC grafts and engraftment
kinetics.
PBSC collections CD34 selected graft Engraftment: time (days) to
CD34+ CD3+ CD34+ CD3+ 500 20,000 100,000 1% RBC
(× 106/kg) PMN Plts Plts ret. LT
1 19.40 ND 3.41 ND 14 13 45 15 21
2 12.33 433 2.07 0.73 20 124 500 30 33
3 10.54 276 1.43 0.30 12 16 36 14 22
4 13.10 127 3.11 0.85 19 37 NA 25 NA
5 15.75 413 2.05 0.92 10 11 28 14 9
6 7.90 181 2.03 0.20 16 NA NA 21 NA
7 13.69 358 6.14 0.03 10 12 33 14 35
8 14.31 458 7.74 0.28 13 17 22 19 11
9 7.06 242 2.05 0.11 15 24 45 21 10
10 8.68 375 4.06 0.10 11 19 NA 21 NA
11 6.49 280 3.87 0.13 11 21 148 130 173
12 8.76 309 5.67 0.26 11 13 18 18 13
13 5.59 302 3.45 0.18 9 15 37 20 NA
14 7.24 315 4.42 0.18 12 13 29 15 35
15 14.98 515 8.01 0.21 9 10 31 15 16
16 11.42 412 6.72 0.05 10 23 NA 14 NA
17 21.02 634 9.40 0.03 10 12 NA NA NA
18 6.57 228 5.65 0.58 11 16 46 18 14
19 13.29 656 5.86 0.01 11 20 NA ND 31
20 6.68 624 2.04 0.24 10 10 14 13 17
21 5.93 435 2.73 0.18 9 23 NA 17 21
22 9.83 648 5.78 0.35 10 11 17 13 35
23 5.73 550 2.79 0.20 9 12 14 16 8
24 10.47 279 7.92 0.48 9 10 17 12 6
Median10.15 375 3.97 0.20 11 15 31 17 19
ND = not done; NA = not achieved; PBSC = peripheral blood stem cells; 
PMN = neutrophils, Plt = platelets, Retic = reticulocytes, LT = last transfusion,
RBC = red blood cells.
Table 3. Composition of lymphocyte infusions.
CD8 cell content Cell content after CD3+ cells infused
before CD8- CD8-depletion (×106/kg R) (×106/kg R)
depletion
(×106/kg R) CD8+ CD4+ CD56+ DLI #1 DLI #2 DLI #3 
cells cells cells (d60) (d100) (d140)
1 161 22.5 107 ND 2 10 50
2 93 1.1 63 40 2 10 50
3 71 0.3 42 12 2 10 41
4 – – – – – – –
5 99 0.3 46 11 2 10 32
6 – – – – – – –
7 169 1.5 ND ND 2 141* –
8 40 0.2 60 9 2 10 26
9 16 0.1 ND ND 2 10 11
10 30 0.4 ND ND 41* – –
11 118 2.8 73 39 2 10 50
12 179 20 89 37 2 – –
13 110 1.7 133 34 2 10 50
14 83 0.6 119 42 10 50 –
15 95 6 109 65 10 50 –
16 – – – – – – –
17 – – – – – –
18 76 0.94 110 ND 10 50 –
19 – – – – – – –
20 98 0.7 46 13 10 40 –
21 41 1.1 102 31 10 50 –
22 126 3.7 ND ND 10 50 –
23 117 4.6 84 24 10 50 –
24 33 0.6 37 16 10 31 –
Median 95 1.1 84 31
R: recipient; ND: not done; –: lymphocyte collection and/or infusion not per-
formed (see text); *after relapse.
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Figure 1. Clinical outcome of the patients.
Table 4. Clinical data.
GVHD CMV Follow-up
Prophylaxis Acute GVHD Chronic GVHD Status Reactivation Other Disease Survival
Drugs Duration Grade Treatment Grade Onset Treatment Don/Rec (PCR+) complications Status Status
(days) (steroids)
1 CyA + Mtx 213 0 No No – No +/– No No CR Alive (d 1344)
2 CyA + Mtx 381 II Yes No – No –/– No No CR Alive (d 1015)
3 CyA 385 II Yes No – No –/– No Pancreatitis Relapse (d 315) Dead (d 950)
4 CyA + Mtx death 0 No No – No +/+ Yes (d 39) MOF CR Dead (d 97)
5 CyA 378 I No No – No +/+ No No CR Alive (d 952)
6 CyA + Mtx death II Yes No – No +/+ Yes (d 25) MOF CR Dead (d 81)
7 CyA 97 I No No – No –/– No No Relapse (d 96) Dead (d 313)
8 CyA + Mtx >559 II Yes Limited d 310 CyA +/+ Yes (d 55) Diabetes CR Alive (d 766)
9 CyA + Mtx >459 I Yes Limited d 255 CyA –/– No Encephalopathy CR Alive (d 686)
10 CyA 60 0 No No – No +/+ Yes (d 26) No Relapse (d 60) Dead (d 99)
11 CyA 273 I No No – No +/+ Yes (d 30) Sepsis (d 85) CR Alive (d 651)
12 CyA death 0 No No – No –/– No No CR Dead (d 70)
13 CyA death 0 No No – No +/+ Yes (d 40) Pleural effusion CR Dead (d 351)
14 CyA 185 I No Extensive d 150 CyA+PDN, UV –/– No No CR Alive (d 449)
15 CyA 150 0 No No – No –/+ Yes (d 25) No Relapse (d 135) Dead (d 309)
16 CyA death 0 No No – No –/– No VOD Refractory Dead (d 44)
17 CyA 10 I No No – No –/+ No No Refractory Dead (d 38)
18 CyA death 0 No Limited d 230 CyA+PDN –/+ Yes (d 32) No CR Dead (d 288)
19 CyA 40 I No No – No +/+ Yes (d 18) Respiratory failure CR Dead (d 195)
20 CyA 315 I No No – No +/– No No CR Alive (d 315)
21 CyA death IV Yes No – No –/– No No CR Dead (d 150)
22 CyA > 168 II Yes No – No +/+ Yes (d 45) Hemorrhagic cystitis CR Alive (d 168)
23 CyA > 126 I No No – No –/– No Encephalopathy CR Alive (d 126)
24 CyA > 140 0 No No – No –/+ Yes (d 52) No CR Alive (d 140)
GVHD = graft–versus–host disease; CMV = cytomegalovirus; Don = donor; Rec = recipient; CyA = cyclosporine A; Mtx = short course of methotrexate; 
PDN = methylprednisolone; CR = complete remission; MOF = multi–organ failure; VOD = veno–occlusive disease of the liver; UVx = photopheresis.
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Collection of donor lymphocytes, CD8
depletion and CD8-depleted DLI
Donor lymphocytes were collected on day 60
from all but 5 donors whose recipients died before
or experienced serious complications (Table 3). As
expected, CD8 depletion reduced the CD8+ cell
count but only by about 1.5 log (435×103 to 14×103
CD8+ cells per 1×106 CD3+ cells, p<0.001), leaving
around 100% CD4+ cells among T-lymphocytes.
After CD8 depletion, the number of CD3+ cells was
sufficient for DLI 1 and 2 in 100% of the cases and
DLI 3 in two thirds of them. On average, 90% (range
40 to 100%) of the scheduled dose of CD8-deplet-
ed lymphocytes could be procured. Infusion of 2, 10
and 50×106 CD3+ cells/kg corresponded to doses of
0.02, 0.1 and 0.5×106 CD8+ cells/kg, respectively.
Clinical data (Figure 1 and Table 4)
Five patients died before receiving DLI. Patients
#6 (second transplant) and #4 developed many
early serious complications and died on day 81 of
influenza pneumonia and on day 99 of a polymi-
crobial infection, respectively. Patient #19 devel-
oped severe renal and respiratory failure and died
of infection at day 195. Patient #16 died of CLL and
veno-occlusive disease of the liver on day 44 and
patient #17 died of leukemia on day 38. The other
19 patients were in CR on day 60 and received the
first DLI. Two ALL patients (patients #7 and 10)
relapsed between days 60 and 100 and received
the pooled 2nd and 3rd aliquots. Patient #7 achieved
a CR with chemotherapy and DLI but relapsed lat-
er and died on day 313. Patient #10 died of
leukemia on day 100. In addition, patient #12 died
suddenly at home of unknown reason while enjoy-
ing continuous CR and presenting no complication
other than depression. The other 16 received the
scheduled 2nd (and the 3rd for patients #1, 2, 3, 5,
8, 9, 10, 13) DLI on days 100 (and 140). Fourteen
of the 16 patients remain in CR 126 to 1344 (medi-
an 400) days post-transplantation. Patient #15
developed a central nervous system relapse on day
135, was reinduced into remission with chemo-
therapy and radiotherapy but relapsed again and
died on day 309. Patient #3 experienced a biopsy-
proven massive relapse in the thymus on day 315
that completely regressed after cyclosporine dis-
continuation, but later relapsed again and she died
on day 950. Finally, 3 patients died in CR after day
100: patient #13 died of pulmonary aspergillosis on
day 351, patient #18 died suddenly at home of
unknown reason on day 288 and patient #21 of
acute grade IV GVHD on day 150. The remaining 11
patients were alive and disease-free 126 to 1344
(median 550) days after transplantation.
Bone marrow chimerism
Evaluation of bone marrow chimerism was per-
formed in 6/7 patients with a donor of the oppo-
site sex (n=7) by FISH with X and Y probes (Figure
2). All of them were more than 98% chimeric on
day 40. Two patients had mixed chimerism on day
100 after transplantation but developed full donor
chimerism on day 180 following pre-emptive CD8-
depleted DLI.
Acute and chronic GVHD (Figure 3)
Acute GVHD occurred in 15 patients. It was of
grade I in 9 patients, of grade II in 5 patients (3
with 1 HLA mismatch) and of grade IV in 1 patient
(HLA mismatch). Thus, grade II-IV acute GVHD
occurred more frequently in HLA-mismatched (4/8
or 50%) than HLA-matched (2/16 or 13%) trans-
plants (p<0.05). Before DLI, the 60-day actuarial
incidence of grade II-IV GVHD was 17% (4
patients) but 2 additional patients developed grade
II and IV GVHD after DLI to produce a 150-day
(after DLI) incidence of 28%. For HLA-identical sib-
ling transplants, the 60- and 150-day actuarial
incidences of grade II-IV acute GVHD were 0 and
13%, respectively (Figure 3A). Chronic GVHD
occurred in 4 patients while cyclosporine was being
tapered off or after it had been discontinued. It
was limited to the liver in 3 patients and extensive
in 1 patient. Three of them (2 limited and 1 exten-
sive) were mismatched transplants and one (limit-
ed) was a matched sibling transplant. The actuar-
ial 2-year incidences of chronic GVHD and exten-
sive chronic GVHD were 37 and 13%, respectively.
For HLA-identical sibling recipients, the figures
were 12 and 0%, respectively (Figure 3B). Finally,
the incidences of acute and chronic GVHD were
quite similar in the 2 schedules of DLI. 
CD8-depleted DLI after CD34-selected allo-PBSCT
Figure 2. Evolution of chimerism in patients with a donor of
the opposite sex.
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CMV reactivation
Eleven of the 24 patients experienced CMV reac-
tivation (PCR positivity) before day 60 that was
successfully reversed by ganciclovir treatment and
none of them presented a clinical CMV infection.
Relapse and survival (Figure 4)
There was no relapse in the 12 standard risk
patients but 6 of the high-risk patients relapsed
(p<0.005) (Figure 4A). The 2-year probability of
relapse was 0% for standard-risk patients and 55%
for high-risk patients (p=0.0085). Analysis of min-
imal residual disease by reverse transcriptase-PCR
in patient #8 demonstrated the persistence of
BCR-ABL fusion transcripts in bone marrow cells
on day 100 after transplantation that disappeared
on day 180 (after DLI). Patients #11 and 22 had no
evidence of residual disease by RT-PCR in any bone
marrow analysis after the transplant. The actuari-
al 2-year probability of survival was 45%, 60% in
standard-risk versus 22% in high-risk patients (Fig-
ure 4B).
Discussion
In agreement with previous studies,17,19,21 CD34-
selection resulted in our study in a 3.3 log elimi-
nation of T-cells while preserving hematologic
reconstitution. Engraftment of neutrophils and
platelets was prompt and significantly faster in
patients who did not receive methotrexate. How-
ever, within the range studied, the number of
F. Baron et al.
Figure 4. A. Cumulative incidence of relapse in standard-risk
(n=12) versus high-risk (n=12) patients. B. Survival rates in
standard-risk (n=12) versus high-risk (n=12) patients.
Figure 3. A. Cumulative incidence of grade II-IV acute GVHD
in HLA-identical (N=16) versus mismatched (N=8) trans-
plants. B. Cumulative incidence of chronic GVHD in HLA-
identical (N=16) versus mismatched  (N=8) transplants.
CD34+ cells did not influence the speed of engraft-
ment significantly. Prompt engraftment occurred
with CD34+ cell doses as low as 1.46×106/kg.
Therefore, CD34-selection preserved the engraft-
ment capability of allogeneic PBSC.
As previously suggested by others,17,22 our results
evidenced that CD34 selection reduces the risk of
acute GVHD. The actuarial 60-day (before DLI) prob-
ability of grade II-IV acute GVHD was 17% in our
study. This rate compares very favorably with results
from studies of HLA-identical siblings receiving
unmanipulated PBSC or BM.4,8 For example in the
most recent report of the Seattle group, the 100-day
incidence of grade II-IV acute GVHD was 64% in
the PBSC group and 57% in the BM group.8
Recent evidence implicates a preparative regi-
men-related cytokine storm in the pathogenesis of
acute GVHD following hematopoietic stem cell
transplantation.44 Therefore, delaying the infusion
of donor lymphocytes until after this storm has
subsided could result in a lower risk of acute GVHD.
We chose to give DLI using CyA prophylaxis
because of a previous report by Barrett et al.45
showing that the risk of grade II-IV acute GVHD
was significant (32%) and the GVL effect preserved
(relapse rate in CML patients considerably less than
after T-cell-depleted BMT without T-cell add-back)
after T-cell-depleted BMT followed by infusion of
substantial (5×107/kg) T-cell doses under cyclo-
sporine prophylaxis. Previous studies have demon-
strated that it is possible to maintain a GVL effect
without GVHD by CD8-depletion of DLI given for
leukemic relapse after BMT.29,34,35,46 Therefore, we
developed an original strategy of pre-emptive infu-
sions of CD8-depleted donor lymphocytes given in
incremental doses after CD34-selected PBSC trans-
plantation. We recognize the heterogeneity of our
patients, but they were treated in an uniform way
and this does not interfere with our evaluation of
GVHD. Nineteen of 24 patients received pre-emp-
tive CD8-depleted DLI and DLI were never with-
held because of GVHD. These DLI were very well
tolerated in patients #1-13 (only 4 patients devel-
oped grade II acute GVHD) leading us to omit the
short course of methotrexate (MTX) even in mis-
matched or older patients and then to infuse high-
er doses of CD8-depleted donor lymphocytes ear-
lier in patients.14-23 These doses again did not
induce any severe acute GVHD except in patient
#21 who developed grade IV acute GVHD and died
of infection and GVHD. Although not all patients
could receive the full third dose because of the sig-
nificant loss of cells in the depletion procedure, on
average 90% of the scheduled dose could be pro-
vided. Although low doses of CD8+ cells were
infused because the degree of CD8+ cell depletion
was moderate (only 1.5 log) and although we
injected more CD4+ cells because the total dose of
T-cells was maintained at 5×107/kg, the procedure
was efficient at preventing severe GVHD. For HLA-
identical sibling transplants, the incidences of
grade II-IV acute GVHD, chronic GVHD and exten-
sive chronic GVHD were 13%, 12% and 0%,
respectively. These incidences are lower than pre-
viously reported in HLA-identical BMT with
methotrexate and CyA as GVHD prophylaxis47 and
even more so in HLA-identical PBSC transplants.8
Therefore, our results show that it is possible to
circumvent GVHD by delaying the addition of donor
lymphocytes after CD34-selected transplantation.
Moreover, our results also compared favorably
with those of previous studies of pre-emptive DLI
after T-cell-depleted BMT or PBSC transplantation.
A few other studies have investigated the feasibili-
ty of adding T-cells back, also to heterogeneous
groups of patients, a few weeks to a few months
after T-cell-depleted (TCD) transplantation. Barrett
gave either 2×106/kg on day 30 and 5×107/kg on
day 45 or 1×107/kg on day 30 to HLA-identical sib-
lings after TCD BMT.45 The probability of grade II-IV
acute GVHD was 32% with schedule 1 and 100%
with schedule 2 and the incidence of chronic GVHD
was 46%. Naparstek gave weekly incremental dos-
es of up to 107/kg before day 28 or 3 incremental
infusions up to 107/kg between day 28 and 84 to
HLA-identical siblings after TCD BMT.38 DLI were
only given to 56% of the patients in group 1 and
their incidence of acute GVHD was 42% but there
was little chronic GVHD. In group 2, the crude inci-
dences of acute and chronic GVHD were 53% and
40%, respectively. Lee administered up to 3 doses
ranging from 105 to 106/kg given between day 0 and
day 100 after related or unrelated transplantation.48
In related transplants, the incidences of acute grade
II-IV GVHD and chronic GVHD were 52% and 56%,
respectively. Martino treated 10 patients after HLA-
matched related CD34-selected PBSC transplanta-
tion but only 4 received a single infusion of 107/kg
donor lymphocytes and all developed chronic
GVHD.39 Recently, Alyea reported on 24 patients
with multiple myeloma who received 1-3×107 CD8-
depleted lymphocytes 6-9 months after a CD6 T-
cell-depleted BMT.49 The authors evidenced a GVL
effect mediated by CD8-depleted DLI. However, only
14/24 (56%) patients received pre-emptive DLI and
DLI induced grade II-IV acute or extensive chronic
GVHD in 7 of them (50%). Thus, compared to our
study, most previous reports used lower doses of T-
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cells and many patients did not receive the sched-
uled DLI, and their incidence of acute and chronic
GVHD was higher. Therefore, CD8-depletion appears
to allow infusions of higher doses of donor lympho-
cytes while minimizing the risk of severe acute or
chronic GVHD.
The mechanism and specificity of the GVL reac-
tion remain uncertain.29,50-53 Although the contri-
bution of CD8+ T-cells cannot be dismissed, results
of CD8-depleted DLI in CML or multiple myeloma
patients suggest that CD4+ T-cells may be the pri-
mary mediators of GVL,29,34,35,49,54,55 at least for these
malignancies. Moreover, for malignancies less sen-
sitive to CD4+ cells, CD4+ T-cells may recruit tumor-
reactive CD8+ T-cells in the host and favor their
amplification.26,29,35 Therefore, pre-emptive infusion
of large doses of CD4+ (and NK) cells in our study
should be expected to preserve the GVL effect. The
relapse rate was much lower than that previously
described after T-cell-depleted transplantation.18
We observed no relapse in the standard-risk
patients and only 55% relapses in the high-risk
patients. Interestingly, whereas previous studies
have shown that the persistence of BCR-ABL tran-
scripts after TCD BMT strongly predicted for
relapse,56 recurrence of CML could be prevented by
DLI in one such patient. The two AML patients in
whom leukemia persisted or recurred after trans-
plant were very high-risk refractory patients, as
was the patient with refractory CLL who also did
not respond to the conditioning regimen. It remains
to be seen whether earlier infusions of higher dos-
es of lymphocytes could have any impact on such
refractory diseases. We conclude that allogeneic
CD34-selected PBSC transplantation followed by
pre-emptive CD8-depleted DLI appears to be a
promising strategy to separate the GVL effect from
GVHD. CD34-selection of the graft and CD8-deple-
tion of DLI resulted in substantial benefits for the
patients in terms of acute and chronic GVHD
despite the large proportion of HLA mismatches.
The use of pre-emptive DLI appeared to maintain
the GVL effect in a high-risk population but this
remains to be demonstrated in more homogeneous
groups of patients. Large randomized studies are
needed to determine whether this strategy could
improve overall survival as well as the quality of life
of the patients and to investigate the infusion of
specific cytotoxic T-lymphocytes instead of CD8-
depleted DLI.
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PEER REVIEW OUTCOMES
What is already known on this topic
Transplantation of CD34+ selected cells from peripher-
al blood of allogeneic donors associates with a lower risk
of acute and chronic graft-versus-host disease than
unmanipulated transplants. Relapse risk may be
increased in this setting, as a consequence of T-cell
depletion, which leads to a decreased graft-versus-
leukemia effect.
What this study adds
CD8-depleted lymphocyte infusions starting on day 60
may be safely administered  without triggering acute or
chronic graft-versus-host disease. The relapse rate after
this approach was similar to that observed in a control
group of non-T-cell depleted transplants.
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This report demonstrates the feasibility of allogeneic
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